Tiziana Graziano Nude - Brightlocal News
Tiziana has submitted a patent application on potential use of foralumab, to improve success of chimeric antigen receptor t cells (car-t) therapy for cancer and other human diseases. The patent … Tiziana is currently conducting clinical trials using intranasal foralumab for non-active secondary progressive multiple sclerosis.
Corporate documents view our latest investor presentation tiziana neuro presentation december 2025 Reductions in microglial activation have been observed in the brains of five of six patients with nonactive secondary progressive multiple sclerosis (spms) who received treatment with tiziana life science’s … Our clinical pipeline includes drug assets for secondary progressive multiple sclerosis, alzheimer’s, and als. Tiziana is led by a team of highly qualified executives with extensive drug development and …